Construction and Validation of a Novel Nomogram Predicting Recurrence in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Post-Surgery Using an Innovative Liver Function-Nutrition-Inflammation-Immune (LFNII) Score: A Bicentric Investigation

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2(1):16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(9 1):4–13. doi:10.1002/hep.31288
   PubMedGoogle Scholar
• Rumgay H, Ferlay J, de Martel C, et al. Global, regional, and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108–118. doi:10.1016/j.ejca.2021.11.023
   PubMed Web of Science ®Google Scholar
• Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2029–2041. doi:10.1111/liv.15251
   PubMed Web of Science ®Google Scholar
• Yoh T, Seo S, Taura K, et al. Surgery for recurrent hepatocellular carcinoma: achieving long-term survival. Ann Surg. 2021;273(4):792–799. doi:10.1097/SLA.0000000000003358
   PubMed Web of Science ®Google Scholar
• Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi:10.1111/liv.14223
   PubMed Web of Science ®Google Scholar
• He H, Chen S, Fan Z, et al. Multi-dimensional single-cell characterization revealed a suppressive immune microenvironment in AFP-positive hepatocellular carcinoma. Cell Discov. 2023;9(1):60. doi:10.1038/s41421-023-00563-x
   PubMed Web of Science ®Google Scholar
• Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. doi:10.1038/s41598-017-12834-1
   PubMed Web of Science ®Google Scholar
• Beale G, Chattopadhyay D, Gray J, et al. AFP, PIVKAII, GP3, SCCA-1, and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer. 2008;8:200. doi:10.1186/1471-2407-8-200
   PubMed Web of Science ®Google Scholar
• Agopian VG, Harlander-Locke MP, Markovic D, et al. Evaluation of patients with hepatocellular carcinoma that do not produce α-fetoprotein. JAMA Surg. 2017;152(1):55–64. doi:10.1001/jamasurg.2016.3310
   PubMed Web of Science ®Google Scholar
• Yan WT, Li C, Yao LQ, et al. Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study. Hepatobiliary Surg Nutr. 2023;12(2):155–168. doi:10.21037/hbsn-21-288
   PubMed Web of Science ®Google Scholar
• Ji J, Wang H, Li Y, et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multicenter study. PLoS One. 2016;11(4):e0153227. doi:10.1371/journal.pone.0153227
   PubMed Web of Science ®Google Scholar
• Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves the detection of BCLC early-stage hepatocellular carcinoma. Z Gastroenterol. 2016;54(12):1296–1305. doi:10.1055/s-0042-119529
   PubMed Web of Science ®Google Scholar
• Huang J, Liu FC, Li L, Zhou WP, Jiang BG, Pan ZY. Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection. Cancer Med. 2020;9(8):2791–2802. doi:10.1002/cam4.2944
   PubMed Web of Science ®Google Scholar
• Wang X, Mao M, He Z, et al. Development and validation of a prognostic nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci. 2019;15(1):221–228. doi:10.7150/ijbs.28720
   PubMed Web of Science ®Google Scholar
• Qiu ZC, Wu YW, Qi WL, et al. Pivka-II combined with Tumor Burden Score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection. Cancer Med. 2023.
   Google Scholar
• Wiseman MJ. Nutrition and cancer: prevention and survival. Br J Nutr. 2019;122(5):481–487. doi:10.1017/S0007114518002222
   PubMed Web of Science ®Google Scholar
• Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL. Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity. J Immunol. 2018;200(2):432–442. doi:10.4049/jimmunol.1701269
   PubMed Web of Science ®Google Scholar
• Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56. doi:10.1038/s41586-019-1593-5
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation, and cancer. Nat Immunol. 2017;18(8):843–850. doi:10.1038/ni.3754
   PubMed Web of Science ®Google Scholar
• Xu L, Yu S, Zhuang L, et al. Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients. Oncotarget. 2017;8(21):34954–34960. doi:10.18632/oncotarget.16865
   PubMedGoogle Scholar
• Huang PY, Wang CC, Lin CC, et al. Predictive effects of inflammatory scores in patients with BCLC 0-A hepatocellular carcinoma after hepatectomy. J Clin Med. 2019;8(10):1676. doi:10.3390/jcm8101676
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y, et al. The systemic immune-inflammation index predicts the prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222. doi:10.1158/1078-0432.CCR-14-0442
   PubMed Web of Science ®Google Scholar
• Wang D, Bai N, Hu X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ. 2019;7:e7132. doi:10.7717/peerj.7132
   PubMed Web of Science ®Google Scholar
• Wang BL, Tian L, Gao XH, et al. Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection. Clin Chem Lab Med. 2016;54(12):1963–1969. doi:10.1515/cclm-2015-1191
   PubMed Web of Science ®Google Scholar
• Li J, Tao H, Zhang E, Huang Z. Diagnostic value of gamma-glutamyl transpeptidase to alkaline phosphatase ratio combined with gamma-glutamyl transpeptidase to aspartate aminotransferase ratio and alanine aminotransferase to aspartate aminotransferase ratio in alpha-fetoprotein-negative hepatocellular carcinoma. Cancer Med. 2021;10(14):4844–4854. doi:10.1002/cam4.4057
   PubMed Web of Science ®Google Scholar
• Li S, Xu W, Liao M, et al. The significance of gamma-glutamyl transpeptidase to lymphocyte count ratio in the early post-operative recurrence monitoring and prognosis prediction of AFP-negative hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:23–33. doi:10.2147/JHC.S286213
   PubMed Web of Science ®Google Scholar
• Mao S, Yu X, Shan Y, Fan R, Wu S, Lu C. Albumin-bilirubin (ALBI) and monocyte-to-lymphocyte ratio (MLR)-based nomogram model to predict tumor recurrence of AFP-Negative hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1355–1365. doi:10.2147/JHC.S339707
   PubMed Web of Science ®Google Scholar
• Wu Q, Zeng J, Zeng J. Inflammation-Related marker NrLR predicts prognosis in AFP-negative HCC patients after curative resection. J Hepatocell Carcinoma. 2023;10:193–202. doi:10.2147/JHC.S393286
   PubMed Web of Science ®Google Scholar
• Yang C, Wu X, Liu J, et al. Nomogram based on platelet-albumin-bilirubin for predicting tumor recurrence after surgery in alpha-fetoprotein-negative hepatocellular carcinoma patients. J Hepatocell Carcinoma. 2023;10:43–55. doi:10.2147/JHC.S396433
   PubMed Web of Science ®Google Scholar
• Ding HF, Yang T, Lv Y, Zhang XF, Pawlik TM, International Hepatocellular Carcinoma Study Group. Development and validation of an α-fetoprotein tumor burden score model to predict post-recurrence survival among patients with hepatocellular carcinoma. J Am Coll Surg. 2023;236(5):982–992. doi:10.1097/XCS.0000000000000638
   PubMed Web of Science ®Google Scholar
• Guo Z. Department of medical administration, National Health and Health Commission of the People’s Republic of China. Zhonghua Gan Zang Bing Za Zhi. 2020;28(2):112–128.
   PubMedGoogle Scholar
• Taniguchi K, Karin M. NF-κB, inflammation, immunity, and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–324. doi:10.1038/nri.2017.142
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Key TJ, Bradbury KE, Perez-Cornago A, Sinha R, Tsilidis KK, Tsugane S. Diet, nutrition, and cancer risk: what do we know and what is the way forward? BMJ. 2020;368:m511. doi:10.1136/bmj.m511
   PubMed Web of Science ®Google Scholar
• Narimatsu H, Yaguchi YT. The role of diet and nutrition in cancer: prevention, treatment, and survival. Nutrients. 2022;14(16):3329. doi:10.3390/nu14163329
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–232. doi:10.1038/s41590-018-0044-z
   PubMed Web of Science ®Google Scholar
• Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver inflammation and hepatobiliary cancers. Trends Cancer. 2021;7(7):606–623. doi:10.1016/j.trecan.2021.01.012
   PubMed Web of Science ®Google Scholar
• De Oliveira S, Houseright RA, Graves AL, et al. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J Hepatol. 2019;70(4):710–721. doi:10.1016/j.jhep.2018.11.034
   PubMed Web of Science ®Google Scholar
• George ES, Sood S, Broughton A, et al. The Association between diet and hepatocellular carcinoma: a systematic review. Nutrients. 2021;13(1):172. doi:10.3390/nu13010172
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020;146(10):2439–2446. doi:10.1007/s00432-020-03331-6
   PubMed Web of Science ®Google Scholar
• Zhang XF, Qi X, Meng B, et al. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems. Eur J Surg Oncol. 2010;36(8):718–724. doi:10.1016/j.ejso.2010.05.022
   PubMed Web of Science ®Google Scholar
• Luo P, Wu S, Yu Y, et al. Current status and perspective biomarkers in AFPnegative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res. 2020;26(2):599–603. doi:10.1007/s12253-019-00585-5
   PubMed Web of Science ®Google Scholar
• She S, Xiang Y, Yang M, et al. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int J Oncol. 2015;47(2):543–554. doi:10.3892/ijo.2015.3042
   PubMed Web of Science ®Google Scholar
• Wang T, Zhang KH. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front Oncol. 2020;10:1316. doi:10.3389/fonc.2020.01316
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang D, Liu C, et al. Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: a multicenter study. Front Immunol. 2023;14:1165510. doi:10.3389/fimmu.2023.1165510
   PubMed Web of Science ®Google Scholar
• Zheng Z, Guan R, Zou Y, et al. Nomogram based on inflammatory biomarkers to predict the recurrence of hepatocellular carcinoma-A multicenter experience. J Inflam Res. 2022;15:5089–5102. doi:10.2147/JIR.S378099
   PubMed Web of Science ®Google Scholar
• Zheng J, Seier K, Gonen M, et al. Utility of serum inflammatory markers for predicting microvascular invasion and survival for patients with hepatocellular carcinoma. Ann Surg Oncol. 2017;24(12):3706–3714. doi:10.1245/s10434-017-6060-7
   PubMed Web of Science ®Google Scholar
• Young S, Cam I, Gencturk M, et al. Inflammatory scores: comparison and utility in HCC patients undergoing transarterial chemoembolization in a North American cohort. J Hepatocell Carcinoma. 2021;8:1513–1524. doi:10.2147/JHC.S335183
   PubMed Web of Science ®Google Scholar
• Wu W, Wang Q, Han D, et al. Prognostic value of pre-operative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection. Cancer Cell Int. 2021;21(1):500. doi:10.1186/s12935-021-02204-3
   PubMed Web of Science ®Google Scholar
• Tian G, Li G, Guan L, Yang Y, Li N. Pre-treatment albumin-to-alkaline phosphatase ratio as a prognostic indicator in solid cancers: a meta-analysis with trial sequential analysis. Int J Surg. 2020;81:66–73. doi:10.1016/j.ijsu.2020.07.024
   PubMed Web of Science ®Google Scholar
• Zhang F, Lu S, Tian M, et al. Albumin-to-alkaline phosphatase ratio is an independent prognostic indicator in combined hepatocellular and cholangiocarcinoma. J Cancer. 2020;11(17):5177–5186. doi:10.7150/jca.45633
   PubMed Web of Science ®Google Scholar
• Dziedzic EA, Gąsior JS, Tuzimek A, Dąbrowski M, Jankowski P. The association between serum vitamin D concentration and new inflammatory biomarkers-systemic inflammatory index (SII) and systemic inflammatory response (SIRI)-in patients with ischemic heart disease. Nutrients. 2022;14(19):4212. doi:10.3390/nu14194212
   PubMed Web of Science ®Google Scholar
• Wang D, Hu X, Xiao L, et al. The prognostic nutritional index and systemic immune-inflammatory index predict the prognosis of patients with HCC. J Gastrointest Surg. 2021;25(2):421–427. doi:10.1007/s11605-019-04492-7
   PubMed Web of Science ®Google Scholar
• Wang RH, Wen WX, Jiang ZP, et al. The clinical value of the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage. Front Immunol. 2023;14:1115031. doi:10.3389/fimmu.2023.1115031
   PubMed Web of Science ®Google Scholar
• Deng-Xiong L, Qing-Xin Y, De-Chao F, et al. Systemic immune-inflammation index (SII) during induction has a higher predictive value than preoperative SII in non-muscle-invasive bladder cancer patients receiving intravesical bacillus Calmette -Guerin. Clin Genitourin Cancer. 2023;21(3):e145–e152. doi:10.1016/j.clgc.2022.11.013
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Raposeiras Roubín S, Abu Assi E, Cespón Fernandez M, et al. Prevalence and prognostic significance of malnutrition in patients with acute coronary syndrome. J Am Coll Cardiol. 2020;76(7):828–840. doi:10.1016/j.jacc.2020.06.058
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Y, Zhang X, Zhang T. Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: a review and meta-analysis. Clin Chim Acta. 2018;486:303–310. doi:10.1016/j.cca.2018.08.030
   PubMed Web of Science ®Google Scholar
• Cristinziano L, Modestino L, Loffredo S, et al. Anaplastic thyroid cancer cells induce the release of mitochondrial extracellular DNA traps by viable neutrophils. J Immunol. 2020;204(5):1362–1372. doi:10.4049/jimmunol.1900543
   PubMed Web of Science ®Google Scholar
• Gershkovitz M, Caspi Y, Fainsod-Levi T, et al. TRPM2 mediates neutrophil killing of disseminated tumor cells. Cancer Res. 2018;78(10):2680–2690. doi:10.1158/0008-5472.CAN-17-3614
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Hyer JM, Diaz A, et al. Synergistic impact of alpha-fetoprotein and tumor burden on long-term outcomes following curative-intent resection of hepatocellular carcinoma. Cancers. 2021;13(4):747. doi:10.3390/cancers13040747
   PubMed Web of Science ®Google Scholar
• Fan Y, Xue H, Zheng H. Systemic therapy for hepatocellular carcinoma: current updates and outlook. J Hepatocell Carcinoma. 2022;9:233–263. doi:10.2147/JHC.S358082
   PubMed Web of Science ®Google Scholar